Axcan Pharma to buy rest of U.S. marketing partner

Article Abstract:

Axcan Pharma Inc is buying the remaining 50% interest in its US marketing partner Axcan Schwarz LLC for $52 million. Axcan Schwarz was formed in Jan 1997 to market a specific formulation of Urso tablets in the US. Urso tablets are used to treat primary biliary cirrhosis, a liver ailment. In August, Axcan acquired Birmingham, AL, drug distributor Scandipharm Inc for $97 million.

Asset sales & divestitures, Acquisitions & mergers, Foreign operations, Drugs Wholesale, Drugs and Druggists' Sundries Wholesalers, Axcan Pharma Inc., Axcan Schwarz LLC

---

No-show U.S. patients hurt TLC

Article Abstract:

Mississauga, Ont.-based TLC Vision Corp. has reported a sharp drop-off in business as clinic patients cancel appointments due to fears over the SARS outbreak. TLC reports that about 60% of its blood dialysis patients come from the United States.

Health aspects, Finance, Health care industry, International aspects, Company financing, Severe acute respiratory syndrome, TLC Vision Corp.

---

N.Y. investors reject AnorMed board proposal

Article Abstract:

The reasons behind the denial of investors over the restructuring plans of AnorMed are presented.

Organizational history, Pharmaceutical preparations, Pharmaceutical industry, Company restructuring/company reorganization, Reorganization and restructuring, Investor relations, Company organization, AnorMED Inc., AOM

Similar abstracts:

• Abstracts: Coal export markets improve. Investors eye U.S. data for clues to inflation. Financing deals edge lower in third quarter
• Abstracts: The best ones start off writing sports. Why are the best men all short, fat and bald? Cry, my beloved country
• Abstracts: Dodge warns SARS will hurt economy. U.S. planning to auction disputed offshore lands
• Abstracts: Mutual Fund Accused of Fraud In Rapid Trading by Managers. 4 Executives At Ahold Unit Are Indicted. Ex-Xerox execs settle SEC charges for $22M
• Abstracts: GM Canada parks at the top of quality survey for 2nd year. How 'Project Jewel' won over Toyota. Ford's new maxim: flex manufacturing

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.